CCA
RPRX icon

Childress Capital Advisors’s Royalty Pharma RPRX Stock Holding History

Childress Capital Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-16
Closed -$1K – 790
2020
Q4 		$1K Buy
+16
New +$679 ﹤0.01% 1061

Other funds holding RPRX

RWJF
Robert Wood Johnson Foundation Princeton, New Jersey $81M AUM 0.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

Childress Capital Advisors's RPRX Position: Q1 2021 in Review

Childress Capital Advisors sold out of Royalty Pharma (RPRX) in Q1 2021, closing a stake of 16 shares — an estimated $1K sold.

Childress Capital Advisors first reported a position in RPRX in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 214 funds tracked by Wall St. Rank hold RPRX as of Q1 2021.

  • Childress Capital Advisors reported no remaining Royalty Pharma position as of Q1 2021 after selling out during the quarter.
  • Childress Capital Advisors sold 16 Royalty Pharma shares in Q1 2021, an estimated $1K.
  • Childress Capital Advisors first reported a position in Royalty Pharma in Q4 2020 and held it in 1 quarter.
  • Childress Capital Advisors's Royalty Pharma position peaked at $1K in Q4 2020.
  • 214 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2021.

Based on Childress Capital Advisors's 13F filing for Q1 2021, filed 21 May 2021.